

Ryan Urak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/138484/publications.pdf>

Version: 2024-02-01

22
papers

936
citations

840776

11
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

1458
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461.		9
2	Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients. <i>Oncolmmunology</i> , 2022, 11, 2040772.	4.6	8
3	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 344-359.	4.1	6
4	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88.	3.4	24
5	Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor. <i>Blood</i> , 2021, 138, 1715-1715.	1.4	1
6	Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity. <i>Blood</i> , 2021, 138, 2796-2796.	1.4	1
7	Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator. <i>Molecular Therapy</i> , 2019, 27, 1737-1748.	8.2	25
8	Improved Cas9 activity by specific modifications of the tracrRNA. <i>Scientific Reports</i> , 2019, 9, 16104.	3.3	19
9	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. <i>Cancer Immunology Research</i> , 2019, 7, 759-772.	3.4	235
10	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018, 24, 106-119.	7.0	136
11	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1380764.	4.6	111
12	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. <i>Nucleic Acids Research</i> , 2018, 46, 7108-7123.	14.5	16
13	Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. <i>Cytotherapy</i> , 2017, 19, 861-866.	0.7	20
14	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. , 2017, 5, 26.		72
15	Comparison of naive and central memory derived CD8 ⁺ effector cell engraftment fitness and function following adoptive transfer. <i>Oncolmmunology</i> , 2016, 5, e1072671.	4.6	25
16	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma. <i>Blood</i> , 2016, 128, 812-812.	1.4	4
17	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. <i>Blood</i> , 2016, 128, 2161-2161.	1.4	0
18	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2993-3002.	7.0	52

#	ARTICLE	IF	CITATIONS
19	Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. <i>Molecular Therapy</i> , 2015, 23, 757-768.	8.2	169
20	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 930-930.	1.4	2
21	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. <i>Blood</i> , 2015, 126, 3086-3086.	1.4	0
22	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. <i>Blood</i> , 2014, 124, 1114-1114.	1.4	1